When do the patents on MOTEGRITY expire, and when will generic MOTEGRITY be available?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Takeda Pharms Usa	MOTEGRITY	prucalopride succinate	TABLET;ORAL	210166-001	Dec 14, 2018	AB	RX	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Takeda Pharms Usa	MOTEGRITY	prucalopride succinate	TABLET;ORAL	210166-002	Dec 14, 2018	AB	RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: August 1, 2026

Motegrity is a prucalopride-based prescription therapy marketed by Takeda for chronic idiopathic constipation (CIC) and opioid-induced constipation (OIC) with established safety/efficacy across multiple clinical programs. The investment case hinges on (1) U.S. patent and exclusivity timing, (2) competitive generic and label-at-risk entry, (3) global supply and commercialization capacity, and (4) whether new line extensions (formulations, new indications, new dosing regimens) create incremental IP or regulatory exclusivity. The decisive variable for investors is whether Motegrity’s remaining enforceable estate blocks meaningful generic entry in the U.S., and how that translates into revenue durability through the late-cycle period.

What patents protect Motegrity (prucalopride) and how strong is the patent estate?

Motegrity’s defensibility in the U.S. is driven by the combination of composition-of-matter, formulation, and method-of-use patent coverage as listed in the FDA Orange Book for prucalopride succinate products. For an investment decision, the key question is not whether patents exist, but whether remaining claims map to the exact commercial product and routes to generic entry.

Which patent categories matter for generic design-arounds?

Composition-of-matter patents: hardest to design around because they cover the active ingredient or closely bound chemical entities.
Formulation patents: can block generic if they require specific compositions, release characteristics, or excipients that are part of the reference product.
Method-of-use patents: can block entry via patent-listed indications or dosing regimens, even when the active ingredient is free to use.

How to map the estate to “at-risk” product facts

Investors should treat the following as the practical “claim chart inputs” when assessing entry risk:

Drug substance: prucalopride succinate.
Dosage form: marketed oral tablets (with strength(s) as listed by FDA).
Indications:
- CIC (adults)
- OIC (adults with chronic non-cancer pain receiving opioids)

The enforceability profile depends on whether Orange Book-listed patents are tied to these indications and whether they still have unexpired claims as of the projected entry window.

What does the Orange Book status imply for investors?

Orange Book status defines the “bright line” for:

Whether Paragraph IV certifications are plausible candidates for U.S. challenges.
Whether a generic can seek approval without infringing.
The availability of 180-day exclusivity for the first challenger.

Motegrity’s investment risk profile is highest when Orange Book lists only limited enforceable patents and those patents are method-of-use or non-core formulation claims that are easier to bypass.

Bottom line for strength assessment: A strong estate is one where unexpired composition-of-matter or core formulation patents persist through the likely generic launch period. A weaker estate is where remaining patents are largely method-of-use with clear design-around pathways.

(Orange Book listing and expiry dates are determinative, but the necessary drug-specific Orange Book patent table content is not provided in the prompt; the analysis therefore cannot state exact patent numbers or expiration dates without risking factual errors.)

When does Motegrity lose exclusivity in the U.S. (patents vs FDA exclusivity)?

For U.S. exclusivity, two distinct mechanisms can delay generics:

Patent expiration and listed patent status in the Orange Book.
Non-patent exclusivity granted by FDA (for example, exclusivity tied to approvals such as New Chemical Entity, New Clinical Investigation, or Pediatric exclusivity), where applicable.

Which timeline drives investor scenarios

If composition-of-matter remains unexpired: generic timelines compress only after those claims expire.
If only method-of-use claims remain: generic timelines depend on whether generics can avoid infringement by omitting the patented indication from labeling or using a different claimed regimen.

How investors translate exclusivity to revenue risk

Late-cycle investors model revenue erosion as a function of:
- time to generic approval,
- time to generic launch after FDA approval,
- payer uptake velocity,
- store of demand among switchable patients.

Motegrity’s revenue durability is typically more sensitive to payer and prescriber switching than to the approval date alone.

How many patents cover Motegrity and what is the coverage breadth across indications?

Coverage breadth is a quality metric:

A high count of patents is not automatically defensive if many are marginally enforceable.
Low count is not automatically weak if the remaining patents are broad and tied to core product features.

Coverage that reduces generic leverage

Multiple independent claims on active ingredient structure.
Multiple formulation patents covering release profile or manufacturing steps that are hard to replicate.
Method-of-use patents that cover both CIC and OIC, limiting label carve-outs.

Coverage that increases generic leverage

Concentration in one indication.
Claims dependent on specific clinical definitions or dosing that can be omitted or adjusted in labeling.

What formulations are protected for Motegrity and how do formulation patents affect generic entry?

For oral products, formulation patents can be decisive if they protect:

dissolution rate,
particle size or solid-state form,
excipient selection that controls release,
manufacturing process controls.

Generic entry design-around logic

A generic can prevail quickly if it can show:

bioequivalence using a different composition, and
absence of infringement with respect to remaining formulation claims.

Investor relevance

Formulation-patent strength correlates to:

time-to-launch uncertainty,
expected litigation cost and settlement probability,
probability that a first generic challenger can commercialize profitably.

What method-of-use (indication/dosing) patents protect Motegrity’s CIC and OIC labels?

Motegrity has two primary indications. Method-of-use patents can protect:

the use in CIC in adults,
the use in OIC in adults with chronic non-cancer pain.

Why method-of-use patents drive Paragraph IV strategy

If Orange Book lists method-of-use patents, a generic challenger can choose:

Paragraph IV for those patents while carving off the patented indication in labeling, or
seeking an approval that triggers a settlement or a non-infringement pathway.

Investor modeling implication

Method-of-use protection is most valuable when:

payers reimburse on a broad indication basis tied to the patented label,
competitors face adoption friction to switch to non-carved label indications.

Which companies are likely to challenge Motegrity with Paragraph IV AND what settlement patterns should investors expect?

In the U.S., the most common path to generic entry is:

FDA approval via ANDA,
Paragraph IV certifications on Orange Book-listed patents,
litigation in federal court,
potential settlement with delayed launch and/or “authorized generic” structures.

Settlement impact framework

Investors should focus on settlement terms that typically matter commercially:

delayed launch date,
whether the challenger keeps 180-day exclusivity or gets redesignated,
whether Takeda licenses an authorized generic to preserve market coverage,
carve-outs for certain strengths or dosing regimens.

No challenger roster is provided in the prompt. Without specific Paragraph IV filings or Orange Book challenger identifiers, naming companies would risk factual errors.

What Motegrity patent litigation affects investors and how do courts typically treat similar oral small-molecule cases?

Investment sensitivity is highest to:

whether the court grants preliminary injunctions,
whether claims are narrowed,
whether settlements occur early,
whether patents are held invalid in whole or in part.

Commercially relevant litigation outcomes

Full invalidation accelerates generic entry sharply.
Partial invalidation can still permit design-around or launch on non-infringing label.
Infringement findings preserve exclusivity and raise the expected value of an ongoing brand.

Because Motegrity-specific litigation records are not included in the prompt, this section cannot quote case outcomes, case numbers, or dates without introducing inaccuracies.

What is the FDA regulatory status of Motegrity (approvals, label, and pathway) and how does it shape competitive risk?

Motegrity (prucalopride) is an FDA-approved oral prescription therapy. The competitive risk depends on whether:

additional regulatory exclusivities were granted on specific label expansions,
new strengths or new dosage forms create additional listing and separate exclusivity pockets,
safety communications materially affect utilization.

Investor relevance of FDA milestones

Key milestones that shape adoption and competition:

label expansion timing,
REMS (if any),
safety label updates that influence prescriber confidence,
postmarketing requirements (timelines and burden).

No FDA revision history or supplemental approvals are provided in the prompt, so this section cannot enumerate concrete FDA events.

What generic entry risks exist for Motegrity in the U.S. (ANDAs, label carve-outs, and bioequivalence)?

Generic entry risk is not binary. It is layered:

ANDA approval (regulatory readiness).
Launch timing (litigation and settlement).
Label scope (carved indications).
Payer behavior (formulary tiering and prior authorization).
Switching friction (patient response history).

The highest-probability entry routes

If patents are mostly method-of-use and can be carved from labeling, generics can launch with narrower label coverage.
If formulation or composition patents remain, generics face longer timelines and higher settlement pressure.

Investment implication

Model “low base” and “high base” cases:

low base: slower generic adoption due to label and payer restrictions,
high base: rapid market share erosion after entry if the label is broadly maintained.

How does Motegrity compare with competing constipation products (revenue exposure and differentiation)?

Motegrity competes in chronic idiopathic constipation and opioid-induced constipation. Investors should evaluate competitive differentiation by:

evidence of symptom improvement magnitude,
tolerability and adverse event profile,
payer placement relative to older prokinetics and secretagogues,
switching dynamics among refractory patients.

Competitive positioning factors investors should price

prescriber comfort with prucalopride vs alternatives,
formulary access under step therapy,
patient persistence and adherence for chronic use.

A full competitor patent-and-regulatory comparison requires competitor-specific Orange Book and exclusivity data not included in the prompt; the investment scenario here is therefore driven primarily by Motegrity’s own exclusivity and entry risk.

Global commercialization and geographic patent coverage: where is Motegrity most exposed?

Geographic risk differs because patent status and filing strategies vary by:

national phase timing,
local enforceability,
regulatory approval and data exclusivity in each market.

Investor checklist for geographic exposure

Identify markets where broad composition-of-matter coverage expires first.
Track local generic launch patterns for small-molecule oral drugs after brand loss of exclusivity.
Assess supply continuity and local manufacturing footprint, which influences launch timing and discounts.

No market-by-market dossier is provided in the prompt; exact country risk mapping is not possible without data.

Investment scenario framework for Motegrity: base, bull, bear cases

Bear case: early enforceability failure or broad invalidation

Court or settlement outcome allows earlier generic launch with broad labeling.
Payer uptake accelerates due to cost pressure.
Brand declines quickly, and pipeline investment must be weighed against margin compression.

Base case: delayed generic entry under remaining Orange Book patents

Entry occurs later, with either carved labeling or litigation delays.
Brand maintains mid-cycle demand, then declines over a longer period.
Settlement preserves some brand cash flow to fund lifecycle strategy.

Bull case: sustained exclusivity and/or effective lifecycle extensions

Remaining core patents keep competition out longer.
Any line extension (new indication, new dosage form, or protected regimen) adds incremental duration.
Authorized generic use (if any) is controlled to limit immediate revenue shock.

The critical missing datapoints for numeric scenario modeling are the specific Motegrity U.S. Orange Book patent expiration dates, FDA exclusivities tied to specific approvals, and any active Paragraph IV litigation timelines.

Key Takeaways

Motegrity’s investment fundamentals are dominated by U.S. Orange Book-listed patent status and whether remaining claims are composition/formulation versus method-of-use.
Generic entry risk depends on the ability to carve patented indications and the practical linkage between listed patents and the commercial label for CIC and OIC.
The most value-relevant due diligence is a claim-to-commercial-product mapping: drug substance, tablet formulation characteristics, and the exact FDA label scope.
Revenue durability is sensitive to launch timing (approval versus actual commercialization) and payer switching speed, not just patent dates.

FAQs

1) What is Motegrity’s primary active ingredient and therapeutic area?
Prucalopride; chronic idiopathic constipation and opioid-induced constipation.

2) How does Orange Book listing determine generic challenge feasibility for Motegrity?
Orange Book patents tied to the approved product and label enable Paragraph IV certifications and associated litigation leverage.

3) Do method-of-use patents for constipation typically block generics or mainly drive label carve-outs?
They often drive label carve-outs, but they can still restrict meaningful entry if payer use is tightly linked to the patented label.

4) What factors most affect how fast generic competitors erode Motegrity pricing after approval?
Payer formulary placement, prior authorization rules, and prescriber switching behavior.

5) What lifecycle events most often extend exclusivity for oral constipation drugs?
New dosage forms, new strengths, protected formulation changes, and label expansions supported by new clinical investigations.

References (APA)

No sources are provided in the prompt, and no drug-specific Orange Book, FDA review, patent register, or litigation records are included.

US Patents:	0
Applicants:	1
NDAs:	1

AI Deep Research

Questions you can ask:

Summary for MOTEGRITY